Details of the Drug

General Information of Drug (ID: DM1EF73)

Drug Name
Methysergide
Synonyms
Deseril; Desernil; Desernyl; Deseryl; Desril; Dimethylergometrin; Methylmethylergonovine; Methysergid; Methysergidum; Metisergide; Metisergido; Sansert; Methyllysergic acid butanolamide; Metisergide [DCIT]; UML 491; Deseril (TN); Methysergidum [INN-Latin]; Metisergido [INN-Spanish]; Sansert (TN); UML-491; Methysergide (USAN/INN); Methysergide [USAN:INN:BAN]; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; 1-Methyl-D-lysergic acid butanolamide; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 1-Methylmethylergonovine; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1], [2]
Therapeutic Class
Vasoconstrictor Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 353.5
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is rapidly absorbed [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Metabolism
The drug is metabolized via the hepatic [3]
Chemical Identifiers
Formula
C21H27N3O2
IUPAC Name
(6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
Canonical SMILES
CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C
InChI
InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15+,19-/m1/s1
InChIKey
KPJZHOPZRAFDTN-ZRGWGRIASA-N
Cross-matching ID
PubChem CID
9681
ChEBI ID
CHEBI:92629
CAS Number
361-37-5
DrugBank ID
DB00247
TTD ID
D0O6GC
VARIDT ID
DR01419

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Antagonist [5], [6], [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Migraine
ICD Disease Classification 8A80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 2C receptor (HTR2C) DTT HTR2C 1.02E-02 -0.45 -0.37
5-HT 2C receptor (HTR2C) DTT HTR2C 2.27E-01 0.27 0.6
P-glycoprotein 1 (ABCB1) DTP P-GP 1.19E-01 -1.32E-01 -2.77E-01
P-glycoprotein 1 (ABCB1) DTP P-GP 1.65E-01 -1.47E-01 -4.48E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methysergide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Methysergide caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [27]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Methysergide caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [27]
Arn-509 DMT81LZ Moderate Increased metabolism of Methysergide caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [27]
Mitotane DMU1GX0 Moderate Increased metabolism of Methysergide caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [27]
Epinephrine DM3KJBC Major Additive hypertensive effects by the combination of Methysergide and Epinephrine. Allergic/hypersensitivity disorder [4A80-4A8Z] [28]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Methysergide caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [29]
Nifedipine DMSVOZT Moderate Decreased metabolism of Methysergide caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [29]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Methysergide caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [27]
Voriconazole DMAOL2S Major Decreased metabolism of Methysergide caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [30]
Posaconazole DMUL5EW Major Decreased metabolism of Methysergide caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [30]
Zafirlukast DMHNQOG Moderate Decreased metabolism of Methysergide caused by Zafirlukast mediated inhibition of CYP450 enzyme. Asthma [CA23] [29]
Ephedrine DMMV0KW Major Additive hypertensive effects by the combination of Methysergide and Ephedrine. Asthma [CA23] [28]
Oritavancin DM28D05 Moderate Increased metabolism of Methysergide caused by Oritavancin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [27]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Methysergide caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [29]
Clarithromycin DM4M1SG Major Decreased metabolism of Methysergide caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Chloramphenicol DMFXEWT Moderate Decreased metabolism of Methysergide caused by Chloramphenicol mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [29]
Troleandomycin DMUZNIG Major Decreased metabolism of Methysergide caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [31]
Telithromycin DMZ4P3A Major Decreased metabolism of Methysergide caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [32]
Erdafitinib DMI782S Moderate Increased metabolism of Methysergide caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [33]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Methysergide caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [27]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Methysergide caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Tucatinib DMBESUA Major Decreased metabolism of Methysergide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [31]
Palbociclib DMD7L94 Moderate Decreased metabolism of Methysergide caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
Pseudoephedrine DMIVJ0D Major Additive hypertensive effects by the combination of Methysergide and Pseudoephedrine. Breathing abnormality [MD11] [28]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Methysergide caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [29]
Secobarbital DM14RF5 Moderate Increased metabolism of Methysergide caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [27]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Methysergide caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [27]
Mifepristone DMGZQEF Major Decreased metabolism of Methysergide caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [34]
Pasireotide DMHM7JS Moderate Decreased metabolism of Methysergide caused by Pasireotide mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [29]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Methysergide caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [29]
Aminoglutethimide DMWFHMZ Moderate Increased metabolism of Methysergide caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [27]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Methysergide caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [29]
MK-8228 DMOB58Q Major Decreased metabolism of Methysergide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [31]
Aprepitant DM053KT Moderate Decreased metabolism of Methysergide caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [29]
Nefazodone DM4ZS8M Major Decreased metabolism of Methysergide caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [35]
Griseofulvin DMK54YG Moderate Increased metabolism of Methysergide caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [27]
LEVONORDEFRIN DMWDJ0H Major Additive hypertensive effects by the combination of Methysergide and LEVONORDEFRIN. Discovery agent [N.A.] [28]
Primidone DM0WX6I Moderate Increased metabolism of Methysergide caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Felbamate DM1V5ZS Moderate Increased metabolism of Methysergide caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Methysergide caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Cenobamate DMGOVHA Moderate Increased metabolism of Methysergide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Phenytoin DMNOKBV Moderate Increased metabolism of Methysergide caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Methysergide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Rufinamide DMWE60C Moderate Increased metabolism of Methysergide caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Phenobarbital DMXZOCG Moderate Increased metabolism of Methysergide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Carbamazepine DMZOLBI Moderate Increased metabolism of Methysergide caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Methysergide caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Mephentermine DMFJH5Q Major Additive hypertensive effects by the combination of Methysergide and Mephentermine. Essential hypertension [BA00] [28]
Oxymetazoline DM8ZXT6 Major Additive hypertensive effects by the combination of Methysergide and Oxymetazoline. Eyelid inflammatory disorder [9A02] [28]
Phenylephrine DMZHUO5 Major Additive hypertensive effects by the combination of Methysergide and Phenylephrine. Faecal incontinence [ME07] [28]
Tazemetostat DMWP1BH Moderate Increased metabolism of Methysergide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [27]
Itraconazole DMCR1MV Major Decreased metabolism of Methysergide caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [30]
Clotrimazole DMMFCIH Moderate Decreased metabolism of Methysergide caused by Clotrimazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Miconazole DMPMYE8 Moderate Decreased metabolism of Methysergide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [36]
Ketoconazole DMPZI3Q Major Decreased metabolism of Methysergide caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [30]
Cimetidine DMH61ZB Moderate Decreased metabolism of Methysergide caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [29]
Dipivefrin DMH5W0G Major Additive hypertensive effects by the combination of Methysergide and Dipivefrin. Glaucoma [9C61] [28]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Methysergide caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [27]
Boceprevir DMBSHMF Major Decreased metabolism of Methysergide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [37]
Telaprevir DMMRV29 Major Decreased metabolism of Methysergide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [37]
Tetrahydrozoline DMT57WC Major Additive hypertensive effects by the combination of Methysergide and Tetrahydrozoline. Herpes simplex infection [1F00] [28]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Methysergide caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [29]
Rifampin DMA8J1G Moderate Increased metabolism of Methysergide caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [27]
Rifapentine DMCHV4I Moderate Increased metabolism of Methysergide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [27]
MK-1439 DM215WE Moderate Increased metabolism of Methysergide caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [27]
Delavirdine DM3NF5G Major Decreased metabolism of Methysergide caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Methysergide caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Cobicistat DM6L4H2 Major Decreased metabolism of Methysergide caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Efavirenz DMC0GSJ Major Decreased metabolism of Methysergide caused by Efavirenz mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Saquinavir DMG814N Major Decreased metabolism of Methysergide caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Etravirine DMGV8QU Moderate Increased metabolism of Methysergide caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [27]
Amprenavir DMLMXE0 Major Decreased metabolism of Methysergide caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Darunavir DMN3GCH Major Decreased metabolism of Methysergide caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Atazanavir DMSYRBX Major Decreased metabolism of Methysergide caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Ritonavir DMU764S Major Decreased metabolism of Methysergide caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Methysergide caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [29]
Levamlodipine DM92S6N Moderate Decreased metabolism of Methysergide caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [29]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Methysergide caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [29]
Amlodipine DMBDAZV Moderate Decreased metabolism of Methysergide caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [29]
Methoxamine DMF5XQH Major Additive hypertensive effects by the combination of Methysergide and Methoxamine. Hypertension [BA00-BA04] [28]
Conivaptan DM1V329 Moderate Decreased metabolism of Methysergide caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [40]
Metaraminol DMWIX23 Major Additive hypertensive effects by the combination of Methysergide and Metaraminol. Hypotension [BA20-BA21] [28]
Lesinurad DMUR64T Moderate Increased metabolism of Methysergide caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [27]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Methysergide caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [29]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Methysergide caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [29]
Amobarbital DM0GQ8N Moderate Increased metabolism of Methysergide caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [27]
Pentobarbital DMFNH7L Moderate Increased metabolism of Methysergide caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [27]
Naphazoline DMJFZDL Major Additive hypertensive effects by the combination of Methysergide and Naphazoline. Itching [1F28-1G07] [28]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Methysergide caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [27]
Crizotinib DM4F29C Moderate Decreased metabolism of Methysergide caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [29]
Brigatinib DM7W94S Moderate Increased metabolism of Methysergide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [27]
Ceritinib DMB920Z Major Decreased metabolism of Methysergide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
PF-06463922 DMKM7EW Moderate Increased metabolism of Methysergide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [27]
Osimertinib DMRJLAT Moderate Decreased metabolism of Methysergide caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [41]
Selpercatinib DMZR15V Moderate Decreased metabolism of Methysergide caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [29]
Idelalisib DM602WT Major Decreased metabolism of Methysergide caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [31]
IPI-145 DMWA24P Moderate Decreased metabolism of Methysergide caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [29]
Vemurafenib DM62UG5 Moderate Increased metabolism of Methysergide caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [27]
LGX818 DMNQXV8 Moderate Increased metabolism of Methysergide caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [42]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Methysergide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [41]
Danazol DML8KTN Moderate Decreased metabolism of Methysergide caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [29]
Exjade DMHPRWG Moderate Increased metabolism of Methysergide caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [27]
Bexarotene DMOBIKY Moderate Increased metabolism of Methysergide caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [27]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Methysergide caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
Nilotinib DM7HXWT Moderate Decreased metabolism of Methysergide caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
Imatinib DM7RJXL Moderate Decreased metabolism of Methysergide caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
Dasatinib DMJV2EK Moderate Decreased metabolism of Methysergide caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
Modafinil DMYILBE Moderate Increased metabolism of Methysergide caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [27]
Netupitant DMEKAYI Moderate Decreased metabolism of Methysergide caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [29]
Entrectinib DMMPTLH Moderate Decreased metabolism of Methysergide caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [29]
Propylhexedrine DMTBW2O Major Additive hypertensive effects by the combination of Methysergide and Propylhexedrine. Obesity [5B80-5B81] [28]
Phenylpropanolamine DMTFK3O Major Additive hypertensive effects by the combination of Methysergide and Phenylpropanolamine. Obesity [5B80-5B81] [28]
Olaparib DM8QB1D Moderate Decreased clearance of Methysergide due to the transporter inhibition by Olaparib. Ovarian cancer [2C73] [27]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Methysergide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [29]
Dopamine DMPGUCF Major Additive hypertensive effects by the combination of Methysergide and Dopamine. Parkinsonism [8A00] [28]
Lanreotide acetate DMG6ZU4 Moderate Decreased metabolism of Methysergide caused by Lanreotide acetate mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [29]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Methysergide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [31]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Methysergide caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [29]
Enzalutamide DMGL19D Moderate Increased metabolism of Methysergide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [27]
Bosentan DMIOGBU Moderate Increased metabolism of Methysergide caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [27]
Nafcillin DMN9RPO Moderate Increased metabolism of Methysergide caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [27]
Norepinephrine DMOUC09 Major Additive hypertensive effects by the combination of Methysergide and Norepinephrine. Sepsis [1G40-1G41] [28]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Methysergide caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [29]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Methysergide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [27]
Larotrectinib DM26CQR Moderate Decreased metabolism of Methysergide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Armodafinil DMGB035 Moderate Increased metabolism of Methysergide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
LEE011 DMMX75K Moderate Decreased metabolism of Methysergide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Pitolisant DM8RFNJ Moderate Increased metabolism of Methysergide caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [27]
Brilinta DMBR01X Moderate Decreased metabolism of Methysergide caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [41]
Elagolix DMB2C0E Moderate Increased metabolism of Methysergide caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [27]
Xylometazoline DMKV32D Major Additive hypertensive effects by the combination of Methysergide and Xylometazoline. Vasomotor/allergic rhinitis [CA08] [28]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Methysergide caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [29]
⏷ Show the Full List of 132 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 134).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012516.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5 Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
6 Intake of fermented soybean (natto) increased locomotor activity in mice. Biol Pharm Bull. 2007 Apr;30(4):845-6.
7 Serotonergic mechanisms of the lateral parabrachial nucleus in renal and hormonal responses to isotonic blood volume expansion. Am J Physiol Regul Integr Comp Physiol. 2007 Mar;292(3):R1190-7.
8 p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90.
9 Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
12 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
13 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
14 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
15 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
16 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
17 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
18 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
19 The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
20 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
21 Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
22 Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
23 Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
24 SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
25 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
26 The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
27 Cerner Multum, Inc. "Australian Product Information.".
28 Barthel W, Glusa E, Koth W "Interactions of dihydroergotamine with etilefrine in human leg veins in vitro and in situ." Int J Clin Pharmacol Ther Toxicol 25 (1987): 63-9. [PMID: 2881898]
29 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
30 Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7. [PMID: 10616689]
31 Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7. [PMID: 314074]
32 Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8. [PMID: 8607732]
33 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
34 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
35 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
36 Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207. [PMID: 9145904]
37 Baldwin ZK, Ceraldi CC "Ergotism associated with HIV antiviral protease inhibitor therapy." J Vasc Surg 37 (2003): 676-8. [PMID: 12618710]
38 Product Information. Cafergot (caffeine-ergotamine). Novartis Pharmaceuticals, East Hanover, NJ.
39 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
40 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
41 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
42 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.